cutaneous squamous cell carcinoma
Oncology · 2020–2023
3decisions
2medicines
3carried consumer input
33individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) that is not curable by surgery or radiation. | Nov 2023 | Recommended with restriction | input received Skin Cancer Advocacy Network · Medical Oncology Group |
| cemiplimab Treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or… | Mar 2022 | Recommended with restriction | 33 individuals Australian Skin Cancer Foundation · Rare Cancers Australia · Skin Cancer Advocacy Network · Melanoma Patients Australia · Medical Oncology Group |
| cemiplimab Treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery… | Nov 2020 | Not recommended | input received Medical Oncology Group · Eastern Cooperative Oncology Group |
Who spoke
Medical Oncology Group · Skin Cancer Advocacy Network · Australian Skin Cancer Foundation · Rare Cancers Australia · Melanoma Patients Australia · Eastern Cooperative Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.